FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021916500> ?p ?o ?g. }

• W2021916500 endingPage "1237" @default.
• W2021916500 startingPage "1233" @default.
• W2021916500 abstract "Objective Tranexamic acid (TA), a synthetic antifibrinolytic drug, has been shown to reduce postoperative bleeding and the need for allogeneic blood transfusion in cardiac surgery. However, the optimal dose regimen of TA is still under debate. The aim of this study was to evaluate whether a lower-dose TA regimen produced equivalent efficacy to its higher-dose counterpart in reducing postoperative bleeding and transfusion needs. Design A prospective, randomized, double-blind trial. Setting National Center for Cardiovascular Diseases & University Hospital, Beijing, People’s Republic of China. Participants One hundred seventy-five patients undergoing cardiac valve surgery were enrolled in the study. Interventions All patients were divided randomly into 2 groups. The lower-dose TA group received a loading dose of 10 mg/kg, maintenance dose of 2 mg/kg/h, and a cardiopulmonary bypass pump prime dose of 40 mg; the higher-dose TA group received a loading dose of 30 mg/kg, maintenance dose of 16 mg/kg/h, and a pump prime dose of 2 mg/kg. Measurements and Main Results The amount of postoperative bleeding, the amount and frequency of allogeneic transfusion, mortality, and morbidities were recorded. There was no significant difference in the volume of 24-hour postoperative bleeding between the lower-dose group and the higher-dose group. Other measurements also showed no statistical difference between the 2 groups, including the amount and frequency of allogeneic transfusion, mortality, and morbidities. Conclusion Lower-dose TA regimen was as effective as the higher-dose regimen in reducing postoperative bleeding and transfusion needs in patients undergoing cardiac valve surgery. Tranexamic acid (TA), a synthetic antifibrinolytic drug, has been shown to reduce postoperative bleeding and the need for allogeneic blood transfusion in cardiac surgery. However, the optimal dose regimen of TA is still under debate. The aim of this study was to evaluate whether a lower-dose TA regimen produced equivalent efficacy to its higher-dose counterpart in reducing postoperative bleeding and transfusion needs. A prospective, randomized, double-blind trial. National Center for Cardiovascular Diseases & University Hospital, Beijing, People’s Republic of China. One hundred seventy-five patients undergoing cardiac valve surgery were enrolled in the study. All patients were divided randomly into 2 groups. The lower-dose TA group received a loading dose of 10 mg/kg, maintenance dose of 2 mg/kg/h, and a cardiopulmonary bypass pump prime dose of 40 mg; the higher-dose TA group received a loading dose of 30 mg/kg, maintenance dose of 16 mg/kg/h, and a pump prime dose of 2 mg/kg. The amount of postoperative bleeding, the amount and frequency of allogeneic transfusion, mortality, and morbidities were recorded. There was no significant difference in the volume of 24-hour postoperative bleeding between the lower-dose group and the higher-dose group. Other measurements also showed no statistical difference between the 2 groups, including the amount and frequency of allogeneic transfusion, mortality, and morbidities. Lower-dose TA regimen was as effective as the higher-dose regimen in reducing postoperative bleeding and transfusion needs in patients undergoing cardiac valve surgery." @default.
• W2021916500 created "2016-06-24" @default.
• W2021916500 creator A5001743625 @default.
• W2021916500 creator A5003751733 @default.
• W2021916500 creator A5013105710 @default.
• W2021916500 creator A5014845250 @default.
• W2021916500 creator A5032043483 @default.
• W2021916500 creator A5047411423 @default.
• W2021916500 creator A5055943272 @default.
• W2021916500 creator A5062796135 @default.
• W2021916500 creator A5065581026 @default.
• W2021916500 creator A5088725738 @default.
• W2021916500 date "2014-10-01" @default.
• W2021916500 modified "2023-09-26" @default.
• W2021916500 title "Comparison of Two Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery" @default.
• W2021916500 cites W148514572 @default.
• W2021916500 cites W1508356601 @default.
• W2021916500 cites W1582615997 @default.
• W2021916500 cites W1983199628 @default.
• W2021916500 cites W1987286654 @default.
• W2021916500 cites W1993653149 @default.
• W2021916500 cites W1999223726 @default.
• W2021916500 cites W2016848644 @default.
• W2021916500 cites W2019179832 @default.
• W2021916500 cites W2022045958 @default.
• W2021916500 cites W2023815739 @default.
• W2021916500 cites W2036454015 @default.
• W2021916500 cites W2049036705 @default.
• W2021916500 cites W2053266732 @default.
• W2021916500 cites W2055178731 @default.
• W2021916500 cites W2068024156 @default.
• W2021916500 cites W2069792508 @default.
• W2021916500 cites W2071688536 @default.
• W2021916500 cites W2073529369 @default.
• W2021916500 cites W2096459479 @default.
• W2021916500 cites W2096876696 @default.
• W2021916500 cites W2100390758 @default.
• W2021916500 cites W2107522704 @default.
• W2021916500 cites W2110228986 @default.
• W2021916500 cites W2110474007 @default.
• W2021916500 cites W2133092517 @default.
• W2021916500 cites W2134802683 @default.
• W2021916500 cites W2138270052 @default.
• W2021916500 cites W2140624242 @default.
• W2021916500 cites W2151479270 @default.
• W2021916500 cites W2155007797 @default.
• W2021916500 cites W2326405647 @default.
• W2021916500 cites W4247907436 @default.
• W2021916500 doi "https://doi.org/10.1053/j.jvca.2013.10.006" @default.
• W2021916500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24447498" @default.
• W2021916500 hasPublicationYear "2014" @default.
• W2021916500 type Work @default.
• W2021916500 sameAs 2021916500 @default.
• W2021916500 citedByCount "19" @default.
• W2021916500 countsByYear W20219165002015 @default.
• W2021916500 countsByYear W20219165002017 @default.
• W2021916500 countsByYear W20219165002018 @default.
• W2021916500 countsByYear W20219165002019 @default.
• W2021916500 countsByYear W20219165002020 @default.
• W2021916500 countsByYear W20219165002021 @default.
• W2021916500 countsByYear W20219165002022 @default.
• W2021916500 countsByYear W20219165002023 @default.
• W2021916500 crossrefType "journal-article" @default.
• W2021916500 hasAuthorship W2021916500A5001743625 @default.
• W2021916500 hasAuthorship W2021916500A5003751733 @default.
• W2021916500 hasAuthorship W2021916500A5013105710 @default.
• W2021916500 hasAuthorship W2021916500A5014845250 @default.
• W2021916500 hasAuthorship W2021916500A5032043483 @default.
• W2021916500 hasAuthorship W2021916500A5047411423 @default.
• W2021916500 hasAuthorship W2021916500A5055943272 @default.
• W2021916500 hasAuthorship W2021916500A5062796135 @default.
• W2021916500 hasAuthorship W2021916500A5065581026 @default.
• W2021916500 hasAuthorship W2021916500A5088725738 @default.
• W2021916500 hasConcept C126322002 @default.
• W2021916500 hasConcept C141071460 @default.
• W2021916500 hasConcept C162156334 @default.
• W2021916500 hasConcept C168563851 @default.
• W2021916500 hasConcept C2778789114 @default.
• W2021916500 hasConcept C2778881276 @default.
• W2021916500 hasConcept C2779637338 @default.
• W2021916500 hasConcept C2780014101 @default.
• W2021916500 hasConcept C2781413609 @default.
• W2021916500 hasConcept C2991743468 @default.
• W2021916500 hasConcept C35294091 @default.
• W2021916500 hasConcept C42219234 @default.
• W2021916500 hasConcept C71924100 @default.
• W2021916500 hasConceptScore W2021916500C126322002 @default.
• W2021916500 hasConceptScore W2021916500C141071460 @default.
• W2021916500 hasConceptScore W2021916500C162156334 @default.
• W2021916500 hasConceptScore W2021916500C168563851 @default.
• W2021916500 hasConceptScore W2021916500C2778789114 @default.
• W2021916500 hasConceptScore W2021916500C2778881276 @default.
• W2021916500 hasConceptScore W2021916500C2779637338 @default.
• W2021916500 hasConceptScore W2021916500C2780014101 @default.
• W2021916500 hasConceptScore W2021916500C2781413609 @default.
• W2021916500 hasConceptScore W2021916500C2991743468 @default.
• W2021916500 hasConceptScore W2021916500C35294091 @default.
• W2021916500 hasConceptScore W2021916500C42219234 @default.

• next